Copy

In This Issue:

  • Off to a Fabulous Start for 2018
  • Go Luke! Luke Timmerman Is Hiking to the Top of Mt. Everest for Cancer Research
  • Novateur Client AIT Therapeutics Announces $9.82 Million Private Placement
  • Novateur Client Innovative Targeting Solutions Announces Research Agreement With Lilly

Featured Events:

  • Seattle Cancer Summit (Top Global IO CEOs & Investors Meeting)
  • Boston Cancer Summit (Top Global IO CEOs & Investors Meeting)
  • 20th Annual LifeSciences BC Awards Dinner
  • BIO International Convention 2018
Ali Ardakani
Managing Director, Novateur
Off to a Fabulous Start for 2018

Attending both JP Morgan Conference in January and BIO CEO & Investor Conference in February confirmed several key points:

  • 2018 will see more licensing deals, M&As, financing & IPOs
  • Pharma will start coming back to look at large target areas and traditional blockbusters
  • FDA is more industry friendly than before
Read more >
Go Luke! Luke Timmerman Is Hiking to the Top of Mt. Everest for Cancer Research

When I found out Luke Timmerman is raising funds for cancer research by hiking the tallest mountain in the world, admittedly I was both excited and jealous!

Read more >

Updates from Novateur Portfolio Clients

AIT Therapeutics Announces $9.82 Million Private Placement
View the press release >
Innovative Targeting Solutions Announces Research Agreement with Lilly
View the press release >

Climb to Fight Cancer: Everest!

Go Luke! Journalist Luke Timmerman on His Quest to Climb Mt. Everest for Cancer Research
Luke Timmerman
Biotechnology journalist, author and entrepreneur

Join Luke Timmerman on his quest to the summit of Mt. Everest, the highest mountain in the world, to support cancer research at Fred Hutch.

Landing Page for Luke's Everest Fundraiser for Cancer Research >
October Announcement of Luke's Climb to Mt. Everest >
January Training Update for Luke's Climb to Mt. Everest >

Also check out the Long Run Podcast: this short summary of the show makes the same basic analogy you do about drug discovery being like an endurance sport, and requiring a mental toughness and resilience. 

Listen to the Long Run Podcast >
Watch Video: Climbing Mt. Everest to Cure Cancer

Upcoming Events: Don't Miss Out

20th Annual LifeSciences BC Awards Dinner

April 19, 2018 — Vancouver, BC



20th Annual LifeSciences BC Awards is an opportunity to celebrate our community’s many achievements, small wins and big victories, with our peers, family and friends. This is our moment to recognize and honour the efforts of all those who have invested their life’s work in mastering successful health outcomes.
More information & registration >
BIO International Convention 2018

June 4-7, 2018 — Boston, MA

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
More information & registration >
#BIO2018 on Twitter >

Past Events

Seattle & Boston Global Cancer Summit

As part of supporting Luke’s quest to conquer Mt. Everest, Novateur (together with Sanofi, 10X Genomics, Takeda, 5AM Ventures, Sofinnova, Arch, EBD, Alnylam and Loncar) was proud to co-sponsor two top tiered industry/venture capital Immuno-Oncology conferences with a roster of “A-List Speakers”. 

Atendees were able to meet "The Who Is Who" of the global Immuno-Oncology landscape (biotech CEOs, large pharmas and VCs) at two meetings in Seattle (March 5th) or Boston (March 7th). Speakers included the head of Oncology and Immuno-Oncology of most major pharma, and CEO of top Immuno-oncology companies including Sunil Agarwal, President of Juno.

For a full list of speakers click below. 
These meetings were sold out!

March 5, 2018 — Seattle, WA >
March 7, 2018 — Cambridge, MA >
Seattle Cancer Summit Gallery:
View full gallery >
Boston Cancer Summit Gallery:
View full gallery >
BIO CEO & Investor Conference 2018

February 12-13, 2018 — New York, NY

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
More information >
#BIOCEO18 on Twitter >
Ali Ardakani, Managing Director of Novateur at the BIO CEO & Investor Conference 2018 in New York City

Client Testimonials

"Novateur engaged the appropriate thought leaders and helped us understand the market and its challenges and the appropriate path through development that would support the positioning of our asset to allow us to capture value and was invaluable to our decision making process.
More than anything, Novateur has taught us that being first-in-class is not enough and that you need to have a well thought out plan to execute on."

— Michael L. Gallo, PhD
President

"The Novateur Ventures’ team guided us to the next level, bringing knowledge, experience and credibility to our team. Simply put, it was like having a world class scientific advisory board, BD team, drug development team simultaneously!"

— Dr. Frederic Leduc
Co-founder & CEO

"Novateur team were able to help us address a number of critical commercial and regulatory issues facing one of our start-up companies working in the cell therapy field. Novateur delivered actionable recommendations that allowed us to deliver a clear and complete business plan to potential investors."

— Steven J. Klein, PhD, MBA
Vice-President, Business Development
Novateur Client Testimonials >

Novateur Article

How to Climb the Life Sciences Mountain

The challenges facing the life sciences sector are well documented, even if there is some debate about which ones are most urgent. From cost and pricing pressures to regulatory compliance, the barriers to success can be significant.

As a result, the mantra “fail it fast” has become a truism. The journey to commercialization is long and expensive; if something isn’t going to succeed, it’s better to know early so that scientists and investors can move on to the next project.

But what about innovations that fail because the teams behind them were missing critical knowledge? How many promising products would live to see the market if their journey was guided by experts who had travelled the route before?

Read in Insights magazine >
Download Novateur article >
Get in Touch
Download Novateur presentation >

Call Us
+1 844 200 6682 (NOVA)
Toll Free USA & Canada







This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Novateur Ventures Inc. · 1055 West Georgia Street · Suite 2100 · Vancouver, BC V6E 3P3 · Canada

Email Marketing Powered by Mailchimp